Main > A1. CORP. INDEX. In-Iz > Incyte/P C2
This data is not available for free
Incyte/P C2's subsections
2000. 08.14.2000. (Focus)
2000. 08.14.2000. (Web-Site)
2001. 08.13.2001. (ADME/SNP)
2002. 03.11.2002. (SoftWare)
2002. 07.22.2002. (Focus)
2002. 10.14.2002. (Contact)
2002. 10.14.2002. (Genomics Drugs)
2002. 10.14.2002. (Parent of)
2002. 11.18.2002. (Contact)
2002. 11.18.2002. (Parent of)
2005. 11.21.2005. (CCR2 AntAgonist)
2006. 08.14.2006. (CEO)
2007. 12.21.2007. (Corp. Sale) >
2012. 10.22.2012. (Exec VP & CCO)
2012. 11.15.2012. (Rheuma.>RA)
2013. 04.29.2013. (Onco.>Liver C.)
2013. 08.21. Onco.>Pancreas C.
2014. 01.13. Pres. & CEO
2014. 07.30. Onco.>NSCLC>Genentech
2014. 10.02. Onco.>MF
2015. 01.09. Onco.>Ab.>Agenus
2015. 03.17. Onco.>PV
2015. 04.14. EU>HQ>CH>Geneva
2015. 07.07. Vanderbilt Uni.
2015. 09.02. Jiangsu Hengrui Medici
2016. 04.06. GVHD>Ruxolitinib
2016. 05.09. Acq. Ariad EU Operatio
2017. 10.25. MacroGenics
2019. 05.24. GVHD>Ruxolitinib
2020. 01.13. Onco.>TafasitaMAb
2020. 05.06. Onco.>NSCLC>USA>OK
2020. 06.29. Onco.>NSCLC>JP>OK
2020. 07.31. Onco.>DLBCL>USA>OK
2021. 09.21. Derma.>AD>USA>OK
2021. 09.22. GVHD>Ruxolitinib>USA>O
2022. 05.05. GVHD>Ruxolitinib>EU>OK
2022. 05.11. COVID-19>Baricitinib
2022. 07.18. Derma.>Vitiligo>USA>OK
2022. 08.26. Onco.>MLNs>USA>OK
2022. 09.15. Onco.>Cholangiocarcino
2023. 03.22. Onco.>MCC>USA>OK
2023. 03.27. Onco.>MLNs>JP>OK
2023. 04.20. Derma.>Vitiligo>EU>OK
Incyte San Diego/P
Patents
Web-Site
Z - OK
Incyte/P C2's products
This section has no products